WO2001000241A2 - Novel vector complexes and their use in gene therapy - Google Patents
Novel vector complexes and their use in gene therapy Download PDFInfo
- Publication number
- WO2001000241A2 WO2001000241A2 PCT/EP2000/005371 EP0005371W WO0100241A2 WO 2001000241 A2 WO2001000241 A2 WO 2001000241A2 EP 0005371 W EP0005371 W EP 0005371W WO 0100241 A2 WO0100241 A2 WO 0100241A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- vector
- complex according
- complex
- cationic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- vectors for gene therapy have so far been nucleic acid sequences which are complexed with a non-viral carrier (e.g. cationic lipids or cationic polymers) or inserted into a virus.
- a non-viral carrier e.g. cationic lipids or cationic polymers
- RES reticuloendothelial system
- the causes of rapid elimination are varied. They can be too large a negative or positive charge, a too large volume or an opsonization of the vector particles by blood proteins.
- viral vectors they can furthermore be the binding of the virus envelope proteins to virus-specific receptors in the organs and / or also antibodies or immune cells specific for the viruses which bind to the vectors and thereby eliminate them.
- Vector particle size inhibited the aggregation of the vectors with themselves or with blood cells, reduced the opsonization of vectors by binding immunoglobulins, complement factors, fibrinogen or fibronectin, protected (adeno-) viral vectors from being eliminated by antibodies (Chillon et al., Gene Ther 5: 995, 1998) and caused an increase in the blood retention time of
- the invention relates to a new vector for gene therapy consisting of the following components:
- Component a) can be an unmodified or modified DNA sequence or an unmodified or modified RNA sequence.
- the nucleotide sequence can perform an anti-DNA (triplex) or anti-RNA (antisense; ribozyme) function or code for an RNA sequence acting in this way or for a protein.
- the nucleotide sequences and their modification can be such that the
- Nucleotide sequence is largely resistant to degradation by DNAsen or RNAsen. Examples of such nucleotide sequences and their modifications are in Breaker, Nature Biotechnol. 15: 427, 1997; Gerwik, Critical Reviews in Oncogenesis 8: 93, 1997; Mukhopadhyay et al., Crit. Rev. Oncogen. 7: 151, 1996; Mercola et al., Cancer Gene Ther. 2: 47, 1995; Frank-Kamenetski, Annu. Rev. Biochem. 64: 65, 1995 and Fraser et al., Exp. Opin. Invest. Drugs 4: 637, 1995.
- the DNA sequence can be linear or circular, for example in the form of a plasmid.
- Component a) can also be a virus, preferably a virus, into which a nucleic acid sequence foreign to the virus has been inserted using the methods known to those skilled in the art.
- viruses are RTV, AV, AAV, HSV, vaccinia viruses, influenza viruses.
- RTV Radio Transmission Tube
- AV Gene Ther. 7
- AAV AAV
- HSV vaccinia viruses
- influenza viruses Such and further examples are from Vile, Nature Biotechnol. 15: 840, 1997; McKeon et al., Human Gene Ther. 7: 1615, 1996; Flotte et al., Gene Ther. 2: 357, 1995; Jolly, Cancer Gene Ther. 1:51, 1994; Dubensky et al., J. Virol. 70: 508, 1996.
- Component b) represents any cationic carrier.
- cationic carriers are cationic lipids, for example described by Kao et al., Oncology Reports 5: 625, 1998, Liu et al., J. Biol. Chem. 270: 24864, 1995; Feigner, Human Gene Ther. 7: 1791, 1996; Ledley, Human Gene Ther. 6: 1129, 1995; Goyal et al., J. Liposom. Res. 5: 49, 1995; Thierry et al., Gene Ther. 4: 226, 1997; Schofield et al., Br. Med. Bull. 51: 56, 1995; Behr, Bioconj. Chem. 5: 382, 1994; Cotten et al.,
- Cationic polymers also include, for example, cationized albumin. Production and use of cationized albumin has been used in the
- Patent application EP-A 0 790 312 described.
- component b) is a polyethyleneimine (PEI), in a further particular embodiment of this invention the polyethyleneimine has a molecular weight in a range from 500-20,000 Da and in a further embodiment has an average molecular weight of about 2000 Da and was prepared as described in patent application EP-A 0 905 254.
- PEI polyethyleneimine
- Component c) represents any polymer with more than 3 cationic and more than 3 anionic charges.
- the ratio of cationic to anionic charges should only be in the range between 3:10 and Fluctuate 10: 3.
- the ratio 1 ( ⁇ 20%): 1 ( ⁇ 20%) should preferably be used.
- the charges can be non-uniform, random or evenly distributed over the polymer.
- preference is given to polymers with a uniform distribution of the cationic and anionic charge.
- preference is furthermore given to polymers with cationic and anionic charge, the isoelectric point of which is in the pH range from 3-9.
- the polymer according to the invention is albumin.
- This albumin can be isolated from the blood or produced recombinantly.
- the albumin is purified human albumin from the serum. The purification and properties of albumin have been described, for example, by T. Peters in FW Putnam "The Plasma Proteins", Academic Press, New York 1975, pp. 133-181.
- Human serum albumin is a single chain polypeptide chain (610 amino acids) with an isoelectric point of 4.7 and approximately 101 positive and 101 negative charges, which are evenly distributed over the entire polypeptide chain.
- component a) is complexed with component b) and this complex is in turn complexed with component c).
- Another embodiment of the invention is that the complexes of components a) and b) in liposomes, preferably anionic liposomes [prepared, for example, as in U.S. Patent No. 4,946,787, U.S. Patent No. 4,245,737, U.S. Patent No. 5,480,463, Heywood and Eanes, Calc , Tissue int. 40: 149, 1992; Lee and Huang, J. Biol. Chem. 271: 8481, 1996; Balicki and Beutler, Blood 88: 3884, 1996; Lucie et al., J. Lip. Res.
- the invention furthermore relates to the addition of the preparation according to the invention by adding a component d).
- This component d) represents a ligand which binds with component a) or component b) or component c) and at the same time has a binding site for the target cell.
- ligands can be
- component d) can also be inserted into a liposome, preferably an anionic liposome, for example as described in US Pat. Nos. 5,252,348 and 5,753,258.
- the target cell-specific protein or peptide selected from one of the aforementioned groups, is to be conjugated to a lipid, for example as described in US Pat. No. 5,662,930.
- a lipid for example as described in US Pat. No. 5,662,930.
- Invention is the target cell-specific protein or peptide associated with a fusiogenic peptide and this in turn with a lipid.
- fusogenic peptides are described in detail in patent applications EP-A 0 846 772 and DE19850987.1 (not yet published).
- the conjugation of the target cell-specific protein or peptide with a fusiogenic peptide is preferably carried out by expression as a recombinant fusion protein using the methods known to the person skilled in the art.
- the vector according to the invention consisting of components a), b) and c) or a), b), c) and d) is produced, for example, in such a way that in the first step component d) with component a), b) and / or c) in the molar ratio [d): a), b) and / or c)] of 1: 1 to 1000: 1, preferably between 10 : 1 and 100: 1 is mixed, hereinafter
- component a) [either alone or in a complex with component d)] is mixed with component b) [in a complex with component d) or alone], preferably in a molar ratio [a) ( ⁇ d): b ) ( ⁇ d)] from 1: 1 to 1: 1000, the mixing ratio being adjusted so that the net charge of the resulting overall complex is preferably either cationic or anionic and below
- the complex resulting from step 2) is mixed with component c) [in complex with d) or alone] in such a way that component c) is in excess, measurable by the fact that the net charge of the from step 2) resulting complex was completely neutralized by step 3), preferably that the mixture of free albumin and albumin-containing complexes resulting from step 3) has a slightly anionic to neutral net charge, further preferably the albumin-containing complex has its isoelectric point in pH Has a value range of 4-7.
- Such vector complexes according to the invention are largely shielded by their component c), i.e. their binding and transfection and transduction of cells that do not carry a receptor for component d) within the vector complex according to the invention is largely reduced.
- the residence time is significantly extended, after administration in the blood circulation, for example, up to several Hours to a few days.
- the vector complexes according to the invention accumulate, for example, in the tumor vessel bed due to the so-called "passive targeting" (Unezaki et al., Int. J. Pharmaceutics 114: 11, 1996; Sadzuka et al., Cancer Lett. 127: 99, 1998 and Wunder et al., Int. J. Oncol. 11: 497, 1997).
- the vector complexes according to the invention bind via their component d) to the target cell and transfect them to release the nucleic acid sequence in the vector complex according to the invention.
- this nucleic acid sequence can develop its effect in the target cell, i.e. For example, inhibit the transcription or translation of a particular gene or a particular RNA, or transduce the cell to express the RNA or the protein encoded by this nucleic acid sequence.
- the vector complexes according to the invention are therefore preferably suitable for in vivo administration with the aim of prophylaxis or therapy of diseases.
- Example 1 Preparation of a vector complex with a plasmid and a target cell-specific multivalent protein.
- the plasmid expression system "pGL3" from Promega was used as component a) and contains the following nucleotide sequences:
- the plasmid was introduced into E. coli bacteria, the bacteria were propagated in culture medium and the plasmids were isolated. Production of component b)
- Low molecular weight polyethyleneimine (PEI-2000) was produced as described in patent application EP-A 0 905 254.
- a 10% strength ethyleneimine monomer solution in water (5 ml of ethyleneimine monomer + 45 ml of distilled water, dissolution with stirring) with the addition of 1% (0.5 ml) of concentrated hydrochloric acid (37 ° C.) as catalyst for 4 days at 50 ° C stirred, evaporated and dried under vacuum at room temperature.
- the molecular weight determinations were carried out by means of laser scattered light measurement (Wyatt Dwan DSP light scattering photometer) at 633 nm after direct injection into a K5 measuring cell. The molar masses are determined on the basis of the calibration constants determined in toluene and the known sample weight.
- Human albumin 20% from Centeon was used as the polymer.
- a multi-functional ligand produced as described in patent application EP-A 0 846 772 is used as component d).
- the hybridoma of the anti-NCAM monoclonal antibody 575/100/2 serves as the starting material for the ZS ligand. About 10 7 cells of this hyridome are removed and the mRNA is extracted from these cells with the aid of an mRNA extraction kit (eg from Pharmacia, Gibco, Qiagen). This mRNA is then transcribed into cDNA by reverse transcription using a cDNA synthesis kit and "random" hexaoligonucleotides (Pharmacia).
- This cDNA serves as a starting material for using variable primers (Clackson et al., Nature 352: 624, 1991) to use the variable heavy chain or the variable light chain of the immunoglobulins by means of a polymerase chain reaction (Saiki et al., Science 230: 1350, 1985 ) to amplify. Restriction sites are simultaneously introduced through the primers in order to clone the fragments into a bacterial expression vector (eg pHENIS, which is derived from pHENI) (Hoogenboom et al., Nucl. Acids Res. 19: 4133, 1991).
- pHENIS which is derived from pHENI
- pelB signal sequence for periplasmic secretion
- histidine tag for purification using immobolized metal affinity chromatography (IMAC)
- IMAC immobolized metal affinity chromatography
- cloning region for the heavy and light chain between a short sequence for a 14 amino acid glycine serine linker coded.
- the heavy and light chains are digested with the appropriate restriction enzymes (VH with Sfil and Xhol; VL with ApaL1 and Notl) and successively cloned into the vector. This creates a recombinant single-chain Fv fragment consisting of the variable heavy chain and light chain, which are covalently linked by a short peptide sequence.
- Recombinant antibodies with specificity for N6-methyladenine are selected from native or semi-synthetic antibody libraries (Nissim et al., EMBO J. 13: 692, 1994) by biopanning on N6-methyladenine-BSA or KLH conjugates.
- the Positive antibody fragments are identified by ELISA in antigen-coated microtiter plates (Nissim et al., EMBO J. 13: 692, 1994).
- Antibodies from these libraries are already in the desired single-chain Fv format and can be used directly for further cloning.
- a fusogenic peptide with the amino acid sequence GLFEALLELLESLWELLLEA (SEQ ID NO .: 1) serves as the linker.
- the coding DNA for this peptide is produced as a double-stranded synthetic oligonucleotide, with suitable restriction cleavage sites (Ascl and Xbal) being appended to the ends.
- Aptl and Xbal suitable restriction cleavage sites
- O1 (5'GGCCGCAGGCTTATTTGAGGCCCTTCTGGAATTGCTAGAGAGCCTCTGGG AATTGCTTCTGGAGGCAT; SEQ ID NO .: 2) and O2 (5'CTAGATGCCTCCAGAAGCAATCCCAGAGGCCTCTAGCAATTCCAGAAGGGo3Co with the manufacturer; Enter 5) for the manufacturer (eg warmed and slowly cooled to room temperature. This double-stranded DNA fragment is used directly for further cloning.
- the complete ligand system is inserted into the expression vector pAB1 (which is similar to pHENIS but has no fusion with g3p) e.g. made in the form of a 3-fragment cloning.
- the starting material is the anti-NCAM single-chain Fv fragment (ZS ligand), which was cut with the restriction enzymes Sfil and Notl, the synthetic linker fragment which contains the cloning sites Notl and Xbal, and the anti-N6-methyladenine single-chain Fv Fragment (GS ligand).
- ZS ligand anti-NCAM single-chain Fv fragment
- Sfil and Notl the restriction enzymes Sfil and Notl
- the synthetic linker fragment which contains the cloning sites Notl and Xbal
- the anti-N6-methyladenine single-chain Fv Fragment GS ligand
- the GS fragment is reamplified with primers which have the restriction sites Xbal or Nbal at the N and C terminus.
- Insert ascl are cloned into the pAB1 vector cut with the restriction enzymes Sfil and Ascl.
- the construct is transformed into suitable bacterial strains, for example E. coli TG1.
- the regulation of the expression of the Ligand system takes place via the bacterial lacZ promoter and is induced by adding IPTG (as described, for example, in McCafferty et al., Appl. Biochem. Biotech. 47: 157, 1994).
- the expressed protein is purified from periplasmic preparations using IMAC (see Griffiths et al., EMBO J. 13: 3245, 1994).
- the total protein has a molecular weight of approximately 55,000 and is present as a monomer.
- the protein recognizes NCAM-expressing tumor cells such as that of small cell bronchial carcinoma and it binds to N6-methylated DNA, which is produced by propagation of the plasmids in bacteria.
- the ligand system is made by incubating the fusion protein with the DNA. The binding to the tumor cell or DNA can be checked by immunofluorescence or ELISA.
- a reporter gene e.g. Luciferase (see component a)
- a ligand system is created that is able to bind to the tumor cells.
- the linker-mediated release from the endosomes takes place, which leads to the transcription and expression of the effector gene.
- the binding of the ligand system to the cell and uptake into the cell can be carried out
- Detect the use of fluorescence-labeled fusion protein and the functionality of the system is based on the detection of the enzymatic activity of luciferase.
- Plasmids [component a)] are suspended in a concentration of 10 9 plasmids / ml in physiological saline.
- the multifunctional ligand [component d)] dissolved in physiological saline, is added in portions to the suspension while shaking, until a molar ratio of about 1:10 (plasmid: multifunctional ligand) is reached.
- the component a) / component d) complex or component a) is then [component b)] PEI-2000 (1 mg / ml physical saline with 1 N HCl adjusted to pH 7.4) in portions until a complete Cationization of the resulting complexes [component a) + d) + b) or component a) + b)] is reached.
- the cationization is determined in the agarose shift assay, in which 50 ⁇ l aliquots are applied to an approximately 0.5 cm thick gel of 1% (w / v) agarose and in Tris-EDTA buffer pH 7.4 at 80 mV Be developed for 2 hours. The location of the DNA was visualized at 254 nm after reaction with ethidium bromide.
- the cationic complexes from components a) + d) + b) are then suspended in an excess of component c) and incubated at 4 ° C. for at least 48 hours. In this excess, complexes are formed from components a) + d) + b) + c), which have a neutral to slightly anionic charge.
- Charge is checked in the agarose shift assay and should be in the range between pH 4 and 7.
- the vector complex according to the invention [component a) + d) + b) + c)] can then be used.
- the vector complex component a) + b) is used as a control.
- Tumor cells expressing NCAM small cell bronchial carcinoma
- melanoma cells MeWo
- fibroblasts 3T3
- Components a) + b) are added to the cells in excess (ratio approx. 20: 1) and the mixture is incubated at 37 ° C. for 1 hour. Below are the Washed cells and incubated for another 60 hours in fresh cell culture medium.
- the successful uptake of the complexes into the cell, the transcription and the expression of the reporter gene in the plasmid are then determined by detecting the luciferase with the aid of the method known to the person skilled in the art and according to information from Promega.
- NCAM-positive cells which are incubated with the vector complex according to the invention [component a) + d) + b) + c)] show a clear expression of luciferase. In contrast, no or only a slight expression is found in the control cells.
- Component c) in the vector complex according to the invention thus prevents the non-ligand-specific transfection of cells.
- mice are injected with the complexes according to the invention [component a) + d) + b) + c)] or, as a control, complexes with components a) + b) into the tail vein.
- the dose is 50 ⁇ g of component a) in the respective complexes per mouse, the suspension medium is physiological saline, the application volume is 250 ⁇ l.
- the animals are anesthetized and bled 30 minutes and 2 hours after the injection.
- the collected blood is mixed with sodium citrate (final concentration 25 mM) and the blood plasma is separated from the blood cells by centrifugation (10 min, 1000 g).
- the DNA is isolated from the whole blood or from the blood plasma using the QIAamp Tissue Kit (Qiagen, Hilden).
- 10 ⁇ l heparin 1000 IU7 ml Novo Nordisk
- Samples of the isolated DNA were applied to 0.8% agarose gel and analyzed by Southern blot as described in detail by Obris et al. 1999 described.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001505948A JP2003503362A (en) | 1999-06-24 | 2000-06-10 | Novel vector conjugates and their use for gene therapy |
AU61496/00A AU6149600A (en) | 1999-06-24 | 2000-06-10 | Novel vector complexes and their use in gene therapy |
EP00947840A EP1196618A2 (en) | 1999-06-24 | 2000-06-10 | Novel vector complexes and their use in gene therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1999129104 DE19929104A1 (en) | 1999-06-24 | 1999-06-24 | Vector complex, useful for gene therapy of e.g. tumors, comprises nucleic acid, cationic carrier, charged polymer and targeting ligand |
DE19929104.7 | 1999-06-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001000241A2 true WO2001000241A2 (en) | 2001-01-04 |
WO2001000241A3 WO2001000241A3 (en) | 2001-08-09 |
Family
ID=7912489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/005371 WO2001000241A2 (en) | 1999-06-24 | 2000-06-10 | Novel vector complexes and their use in gene therapy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1196618A2 (en) |
JP (1) | JP2003503362A (en) |
AU (1) | AU6149600A (en) |
DE (1) | DE19929104A1 (en) |
WO (1) | WO2001000241A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045583A1 (en) * | 2002-11-15 | 2004-06-03 | Nipro Corporation | Liposome |
JP2005298486A (en) * | 2004-03-15 | 2005-10-27 | Nipro Corp | Liposome-containing medicinal composition for treating cancer |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847240A (en) * | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
WO1997012051A1 (en) * | 1995-09-28 | 1997-04-03 | Rhone-Poulenc Rorer S.A. | Pharmaceutical composition useful for nucleic acid transfection, and use thereof |
WO1998006869A1 (en) * | 1996-08-14 | 1998-02-19 | The Children's Hospital Of Philadelphia | Non-viral vehicles for use in gene transfer |
EP0846772A1 (en) * | 1996-11-29 | 1998-06-10 | Hoechst Aktiengesellschaft | Multifunctional ligand system for cell-specific transfer of nucleic acid |
US5972707A (en) * | 1994-06-27 | 1999-10-26 | The Johns Hopkins University | Gene delivery system |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4119590A (en) * | 1975-05-22 | 1978-10-10 | Toyo Soda Manufacturing Co., Ltd. | Process for producing a polyion complex having a nucleic acid base |
US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
DE19605279A1 (en) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use |
GB9623051D0 (en) * | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
-
1999
- 1999-06-24 DE DE1999129104 patent/DE19929104A1/en not_active Withdrawn
-
2000
- 2000-06-10 EP EP00947840A patent/EP1196618A2/en not_active Withdrawn
- 2000-06-10 AU AU61496/00A patent/AU6149600A/en not_active Abandoned
- 2000-06-10 WO PCT/EP2000/005371 patent/WO2001000241A2/en not_active Application Discontinuation
- 2000-06-10 JP JP2001505948A patent/JP2003503362A/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847240A (en) * | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5792645A (en) * | 1989-03-16 | 1998-08-11 | Boehringer Ingelheim International Gmbh | Protein-polycation nucleic acid complexes and methods of use |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5972707A (en) * | 1994-06-27 | 1999-10-26 | The Johns Hopkins University | Gene delivery system |
WO1997012051A1 (en) * | 1995-09-28 | 1997-04-03 | Rhone-Poulenc Rorer S.A. | Pharmaceutical composition useful for nucleic acid transfection, and use thereof |
WO1998006869A1 (en) * | 1996-08-14 | 1998-02-19 | The Children's Hospital Of Philadelphia | Non-viral vehicles for use in gene transfer |
EP0846772A1 (en) * | 1996-11-29 | 1998-06-10 | Hoechst Aktiengesellschaft | Multifunctional ligand system for cell-specific transfer of nucleic acid |
Non-Patent Citations (10)
Title |
---|
BONFILS E ET AL: "DRUG TARGETING: SYNTHESIS AND ENDOCYTOSIS OF OLIGONUCLEOTIDE- NEOGLYCOPROTEIN CONJUGATES" NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, Bd. 20, Nr. 17, 11. September 1992 (1992-09-11), Seiten 4621-4629, XP000461068 ISSN: 0305-1048 * |
DASH P R ET AL: "Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery." GENE THERAPY, Bd. 6, Nr. 4, April 1999 (1999-04), Seiten 643-650, XP000982444 ISSN: 0969-7128 * |
GOTTSCHALK S ET AL: "A NOVEL DNA-PEPTIDE COMPLEX FOR EFFICIENT GENE TRANSFER AND EXPRESSION IN MAMMALIAN CELLS" GENE THERAPY,GB,MACMILLAN PRESS LTD., BASINGSTOKE, Bd. 3, Nr. 5, 1. Mai 1996 (1996-05-01), Seiten 448-457, XP000577712 ISSN: 0969-7128 * |
GUPTA P K ET AL: "ALBUMIN MICROSPHERES II: APPLICATIONS IN DRUG DELIVERY" JOURNAL OF MICROENCAPSULATION,GB,TAYLOR AND FRANCIS INC. LONDON, Bd. 6, Nr. 4, 1. Oktober 1989 (1989-10-01), Seiten 463-472, XP000086853 ISSN: 0265-2048 * |
HAN JUNGHEE ET AL: "Receptor-mediated gene transfer to cells of hepatic origin by galactosylated albumin-polylysine complexes." BIOLOGICAL & PHARMACEUTICAL BULLETIN, Bd. 22, Nr. 8, August 1999 (1999-08), Seiten 836-840, XP000979353 ISSN: 0918-6158 * |
HAN JUNGHEE ET AL: "Receptor-mediated gene transfer to cells of hepatic origin by galactosylated albumin-polylysine conjugates." PHARMACEUTICAL RESEARCH (NEW YORK), Bd. 14, Nr. 11 SUPPL., November 1997 (1997-11), Seite S55, Zusammenfassung Nummer 1171, XP000982439 & Annual Meeting of the American Association of Pharmaceutical Scientists; Boston, US; November 2-6, 1997 ISSN: 0724-8741 * |
KINSEY B. ET AL: "Polmethyleneimine conjugated to macroaggregated albumin mediates high level transfection in vitro and in vivo" PROCEEDINGS OF THE CONTROLLED RELEASE SOCIETY, 1999, NO. 26, PAGE(S) 619-620, XP000982539 & INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, 20. - 25. Juni 1999, BOSTON, US * |
SANDIG M ET AL: "The homophilic binding site of the neural cell adhesion molecule NCAM is directly involved in promoting neurite outgrowth from cultured neural retinal cells" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, Bd. 269, Nr. 20, 20. Mai 1994 (1994-05-20), Seiten 14841-14848, XP002104481 ISSN: 0021-9258 * |
SHEN W -C ET AL: "CONJUGATION OF POLY-L-LYSINE TO ALBUMIN AND HORSERADISH PEROXIDASE:A NOVEL METHOD OF ENHANCING THE CELLULAR UPTAKE OF PROTEINS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES,NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC,US, Bd. 75, Nr. 4, April 1978 (1978-04), Seiten 1872-1876, XP000953474 ISSN: 0027-8424 * |
WU C H ET AL: "TARGETING GENES: DELIVERY AND PERSISTENT EXPRESSION OF A FOREIGN GENE DRIVEN BY MAMMALIAN REGULATORY ELEMENTS IN VIVO" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, Bd. 264, Nr. 29, 15. Oktober 1989 (1989-10-15), Seiten 16985-16987, XP002030967 ISSN: 0021-9258 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045583A1 (en) * | 2002-11-15 | 2004-06-03 | Nipro Corporation | Liposome |
JPWO2004045583A1 (en) * | 2002-11-15 | 2006-03-16 | ニプロ株式会社 | Liposome |
JP4848637B2 (en) * | 2002-11-15 | 2011-12-28 | ニプロ株式会社 | Liposome |
JP2005298486A (en) * | 2004-03-15 | 2005-10-27 | Nipro Corp | Liposome-containing medicinal composition for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
AU6149600A (en) | 2001-01-31 |
JP2003503362A (en) | 2003-01-28 |
EP1196618A2 (en) | 2002-04-17 |
DE19929104A1 (en) | 2000-12-28 |
WO2001000241A3 (en) | 2001-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69535540T2 (en) | COMPOSITION CONTAINING NUCLEIC ACIDS AND CATIONIC POLYMERS, PREPARATION AND USE | |
DE69635609T2 (en) | NUCLEIC ACID COMPOSITION, MANUFACTURE AND USE | |
Behr | Synthetic gene transfer vectors II: back to the future. | |
DE60032739T2 (en) | IMMUNOLIPOSOME WITH A TARGETING ANTIBODY FRAGMENT FOR SYSTEMIC GENERIC ADMINISTRATION | |
CN109475646A (en) | Lipid nanoparticle preparation for CRISPR/CAS ingredient | |
AU705816B2 (en) | Peptides which enhance transport across tissues and methods of identifying and using the same | |
CN112040988A (en) | Modified AAV capsid polypeptides for the treatment of muscle diseases | |
DE69822473T2 (en) | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR ADMINISTRATING NUCLEIC ACID MOLECULES | |
WO2017136520A1 (en) | Mitochondrial genome editing and regulation | |
JP2002515418A (en) | Polymer gene carrier for polyethylene glycol conjugated poly-L-lysine targeting hepatocytes | |
DD294969A5 (en) | THERMALLY STABLE CYTOSINE DEAMINEASE | |
JP2000506865A (en) | Targeted delivery of genes encoding interferons | |
KR20130103562A (en) | Compositions of a peptide targeting system for treating cancer | |
EP0905254A2 (en) | DNA vector associated with biocompatible low molecular weight polyethyleneimines | |
DE112016002962T5 (en) | Family of ATP-binding cassette-encoding polyribonucleotides and formulations thereof | |
EP1270586B1 (en) | Composition for the cell-specific transfer of active substances | |
KR19990063814A (en) | Pharmaceutical compositions useful for nucleic acid transfection and uses thereof | |
US8796027B2 (en) | Nucleic acid complex and method of introducing nucleic acid into cell using the same | |
MXPA01012802A (en) | Copolymers for the transfer of nucleic acids to the cell. | |
EP1196618A2 (en) | Novel vector complexes and their use in gene therapy | |
DE19856052A1 (en) | Conjugate for enrichment in neuronal cells | |
DE19850718C1 (en) | Cell permeability-mediating polypeptide | |
EP1007549B1 (en) | Compositions and methods for highly efficient transfection | |
JP2022502081A (en) | Genetically engineered microorganisms and how to make and use them | |
DE19925143A1 (en) | New liposomal vector complexes and their use for gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000947840 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 505948 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000947840 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000947840 Country of ref document: EP |